Dosimetry and pharmacokinetics of [
Dosimetry
Neuroendocrine tumours
Pharmacokinetics
Somatostatin receptor antagonist
Systemic radionuclide therapy
[177Lu]Lu-satoreotide tetraxetan
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
received:
02
11
2023
accepted:
08
03
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
aheadofprint
Résumé
To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [ This study was part of a phase I/II trial of [ In all evaluated organs, maximum [ [ NCT02592707. Registered October 30, 2015.
Identifiants
pubmed: 38528164
doi: 10.1007/s00259-024-06682-1
pii: 10.1007/s00259-024-06682-1
doi:
Banques de données
ClinicalTrials.gov
['NCT02592707']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ipsen
ID : Ipsen
Informations de copyright
© 2024. The Author(s).
Références
Paganelli G, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41(10):1845–51. https://doi.org/10.1007/s00259-014-2735-5 .
doi: 10.1007/s00259-014-2735-5
pubmed: 24615468
Sansovini M, et al. Treatment with the radiolabelled somatostatin analog 177Lu-Dotatate for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97(4):347–54. https://doi.org/10.1159/000348394 .
doi: 10.1159/000348394
pubmed: 23392072
Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427 .
doi: 10.1056/NEJMoa1607427
pubmed: 28076709
pmcid: 5895095
Hoskin P, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406. https://doi.org/10.1016/s1470-2045(14)70474-7 .
doi: 10.1016/s1470-2045(14)70474-7
pubmed: 25439694
Sartor O, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322 .
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Kratochwil C, et al. Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830–45. https://doi.org/10.1007/s00259-023-06255-8 .
doi: 10.1007/s00259-023-06255-8
pubmed: 37246997
pmcid: 10317889
Maghsoomi Z, et al. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer. 2021;21. https://doi.org/10.1186/s12885-021-08257-x .
Inaki A, et al. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med. 2022;36(3):267–78. https://doi.org/10.1007/s12149-021-01699-0 .
doi: 10.1007/s12149-021-01699-0
pubmed: 34870794
Chicheportiche A, et al. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys. 2020;7(1):5. https://doi.org/10.1186/s40658-020-0273-8 .
doi: 10.1186/s40658-020-0273-8
pubmed: 31975156
pmcid: 6977807
ICRP. Nonstochastic effects of ionizing radiation. ICRP publication 41. Ann ICRP. 1984;14:1–33.
Lassmann M, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405. https://doi.org/10.1007/s00259-008-0761-x .
doi: 10.1007/s00259-008-0761-x
pubmed: 18491092
Lassmann M, Eberlein U. The relevance of Dosimetry in Precision Medicine. J Nucl Med. 2018;59(10):1494. https://doi.org/10.2967/jnumed.117.206649 .
doi: 10.2967/jnumed.117.206649
pubmed: 30002109
Hagmarker L, et al. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-Dotatate treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60(10):1406 https://doi.org/10.2967/jnumed.118.225235 .
Ilan E, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-Dotatate. J Nucl Med. 2015;56(2):177 https://doi.org/10.2967/jnumed.114.148437 .
Alipour R, et al. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with (177)Lu DOTATATE (LuTate). Eur J Nucl Med Mol Imaging. 2023;50(10):2997–3010. https://doi.org/10.1007/s00259-023-06257-6 .
doi: 10.1007/s00259-023-06257-6
pubmed: 37184682
pmcid: 10382388
Eychenne R, et al. Overview of Radiolabeled somatostatin analogs for Cancer Imaging and Therapy. Molecules. 2020;25(17). https://doi.org/10.3390/molecules25174012 .
Zhang J, et al. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020;146(6):1533–43. https://doi.org/10.1007/s00432-020-03181-2 .
doi: 10.1007/s00432-020-03181-2
pubmed: 32281025
Hicks RJ, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105(3):295–309.
doi: 10.1159/000475526
pubmed: 28402980
Ginj M, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103(44):16436–41. https://doi.org/10.1073/pnas.0607761103 .
doi: 10.1073/pnas.0607761103
pubmed: 17056720
pmcid: 1618814
Fani M, et al. Radiolabeled somatostatin Analogs-A continuously evolving class of Radiopharmaceuticals. Cancers (Basel). 2022;14(5). https://doi.org/10.3390/cancers14051172 .
Beykan S, et al. 177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model. EJNMMI Res. 2016;6(1):50. https://doi.org/10.1186/s13550-016-0204-9 .
doi: 10.1186/s13550-016-0204-9
pubmed: 27294582
pmcid: 4906090
Wild D, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor Radionuclide Therapy: a pilot study. J Nucl Med. 2014;55(8):1248–52. https://doi.org/10.2967/jnumed.114.138834 .
doi: 10.2967/jnumed.114.138834
pubmed: 24963127
Reidy-Lagunes D, et al. Phase I Trial of Well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist 177Lu-Satoreotide Tetraxetan. Clin Cancer Res. 2019;25(23):6939–47. https://doi.org/10.1158/1078-0432.Ccr-19-1026 .
doi: 10.1158/1078-0432.Ccr-19-1026
pubmed: 31439583
pmcid: 8382090
Wild D, et al. A phase I/II study of the safety and efficacy of [
Bodei L, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16. https://doi.org/10.1007/s00259-012-2330-6 .
doi: 10.1007/s00259-012-2330-6
pubmed: 23389427
pmcid: 3622744
Krenning EP, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Italian J Gastroenterol Hepatol. 1999;31(Suppl 2):S219–23.
Kletting P, et al. The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys. 2015;25(3):264–74. https://doi.org/10.1016/j.zemedi.2015.01.001 .
doi: 10.1016/j.zemedi.2015.01.001
pubmed: 25791740
Hindorf C, et al. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238–50. https://doi.org/10.1007/s00259-010-1422-4 .
doi: 10.1007/s00259-010-1422-4
pubmed: 20411259
Traino AC, et al. Influence of total-body mass on the scaling of < i > S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol. 2007;52(17):5231–48. https://doi.org/10.1088/0031-9155/52/17/009 .
doi: 10.1088/0031-9155/52/17/009
pubmed: 17762083
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023–7.
pubmed: 15937315
Baum RP, et al. First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor Radionuclide Therapy in patients with metastatic neuroendocrine neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021;62(11):1571. https://doi.org/10.2967/jnumed.120.258889 .
doi: 10.2967/jnumed.120.258889
pubmed: 33674401
pmcid: 8612334
European Medcines Agency. Assessment report EMA/506460/2017: Lutathera. 2017 [cited 2022 28 May 2022]; Available from: https://www.ema.europa.eu/en/documents/assessment-report/lutathera-epar-public-assessment-report_en.pdf .
Health Sciences Authority. Summary Report of Benefit-Risk Assessment: Lutathera. 2020 [cited 2022 28 June 2022]; Available from: https://www.hsa.gov.sg/docs/default-source/hprg-tpb/summary-reports/lutathera_summary-report_01june2020.pdf .
Nautiyal A, Michopoulou S, Guy M. Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review. Clin Translational Imaging. 2023. https://doi.org/10.1007/s40336-023-00589-x .
doi: 10.1007/s40336-023-00589-x
Beykan S, et al. OP-081 patient-specific dosimetry of 177Lu-DOTATATE peptide receptor radionuclide therapy with high activities. Eur J Nucl Med Mol Imaging. 2018;45:S33.
Garske-Román U, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970–88. https://doi.org/10.1007/s00259-018-3945-z .
doi: 10.1007/s00259-018-3945-z
pubmed: 29497803
pmcid: 5915504
Bergsma H, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-Dotatate: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018;59(3):452 https://doi.org/10.2967/jnumed.117.189712 .
Forrer F, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138. https://doi.org/10.1007/s00259-009-1072-6 .
doi: 10.1007/s00259-009-1072-6
pubmed: 19247653
pmcid: 2691529
Das S, et al. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019;13(11):1023–31. https://doi.org/10.1080/17474124.2019.1685381 .
doi: 10.1080/17474124.2019.1685381
pubmed: 31652074
pmcid: 7227421
Food and Drug Administration. NDA 208700. 2017 [cited 2022 28 June 2022]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000OtherR.pdf .
Mansi R, Fani M. Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors. J Label Compd Radiopharm. 2019;62(10):635–45. https://doi.org/10.1002/jlcr.3755 .
doi: 10.1002/jlcr.3755
Childs A, et al. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br J Cancer. 2016;115(12):1540–7. https://doi.org/10.1038/bjc.2016.377 .
doi: 10.1038/bjc.2016.377
pubmed: 27875519
pmcid: 5155369